SABCS 2021

Leading the way for other ct-DNA trials

The risk-adapted decision for or against AI has to be…

Hypothesis-generating study in the HER2-enriched…

Metformin is not an anti-cancer drug

Negative results with hope for translational projects

Solved and unsolved controversies of early breast…

The next standard for TNBC?!

Metformin shows no efficacy for most cancer patients

Re-evaluation confirms old data

Benefit only related to chemotherapy?!

Genomic signatures of DCIS

Critical consideration of the study data is necessary

Molecular-guided treatment is of value in combination…

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Erneute Auswertung bestätigt alte Daten

E’ solo effetto della chemioterapia?

Hypothesen-generierende Studie beim HER2-enriched…

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

Kritische Betrachtung der Studiendaten notwendig

La metformina non può essere considerata un farmaco…

"Signatures Genomiche " nel carcinoma duttale in situ

cTRAK TN: ctDNA monitoring not yet ready for primetime.…

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

HER2+ EBC: Chemotherapy free regimens? Extended…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

Samuraciclib - new targeted therapy for luminal breast…

Immuntherapy for high tumor mutation burden in…

Final results of the CPS score subgroup analyses show…

3 updates - 3 new standards of care

Switching with molecular progress improves PFS

Reconfirming effect of T-DXd in patients with brain…

TROP2 - new target for improved chemotherapy

Pioneering study of personalized medicine in advanced…

IO + IO without resounding success in the mBC setting

Oral SERDs for early setting and adjuvant therapy

More good news for TDXd

Robust benefit of pembroluzimab in addition to…

Chekpoint inhibition in breast cancer

Dato-Dxd for metastatic TNBC

T-Dxd is also active in patients with brain metastasis

Promising results for TNBC patients

Activity of T-Dxd across all Her2-expressing breast…

Precision oncology is beneficial in certain mBC…

Very good news for endocrine resistant metastatic…

Oral SERDs are efficient, but show high progression…

My highlights of 2021 in metastatic breast cancer

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Best of the year: systemic therapy

Effectiveness depending on PDL1 status

Pooled analyses shows OS benefit for most subgroups

Dato-DXd new promising ADC

PFS improvement with fulvestrant in patients with…

Elacestrant - less than we expected

Which patients will benefit from Pembro in metastatic…

Exciting novel therapies for metastatic TNBC

TDXd is very efficient in patients with brain…

Amazing period for patients with refractory metastatic…

Activité du T-DXd dans les metastases cérébrales

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Checkpoint-Inhibition beim Mammakarzinom

Important benefice de l’ajout du pembrolizumab à la…

Resultados finales de los análisis de los subgrupos de…

Elacestrant – poniżej oczekiwań

Werden orale SERDs die Therapie mit Fulvestrant in…

L’imaging mass cytometry può aiutare a predire…

Résultats prometteurs dans le cancer du sein triple…

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Best of the Year: Systemtherapie

Mi retrospectiva del cáncer de mama metastático en 2021

Umstellung bei molekularem Progress verlängert PFS

Wegweisende Daten für die personalisierte Medizin beim…

È un grande momento per i pazienti con tumore mammario…

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Buone notizie per i tumori mammari endocrino resistenti

T-Dxd aktywny również w przerzutach do mózgu

Präzisionsonkologie funktioniert beim mBC

Risultati promettenti nel tumore al seno triplo…

Samuracyklib – nowe leczenie celowane w rakach…

Neues Target für optimierte Chemotherapie

Amélioration de la survie sans progression par le…

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

MBC TNBC: Molecular tumor characteristics define the…

Integrating patients perspectives in metastatic breast…

MBC HR+: What is the best option after a CDK4/6i…

Therapy of brain metastasis – can T-DXd be the new SoC?

New ADCs on the horizon for TNBC patients

Treatment options for patients with metastatic TNBC

Targeting rare mutations in breast cancer - is this the…